Related Experiment Video
Updated: Oct 22, 2025
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
Protective effect of LNA-anti-miR-132 therapy on liver fibrosis in mice
Fatemeh Momen-Heravi1,2,3, Donna Catalano4, Austin Talis1,2
1Cancer Biology and Immunology Laboratory, College of Dental Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Abstract:
microRNAs (miRs) are small regulatory RNAs that are frequently deregulated in liver disease. Liver fibrosis is characterized by excessive scarring caused by chronic inflammatory processes. In this study, we determined the functional role of miR-132 using a locked nucleic acid (LNA)-anti-miR approach in liver fibrosis. A significant induction in miR-132 levels was found in mice treated with CCl4 and in patients with fibrosis/cirrhosis. Inhibition of miR-132 in mice with LNA-anti-miR-132 caused decreases in CCl4-induced fibrogenesis and inflammatory phenotype. An attenuation in collagen fibers, α SMA, MCP1, IL-1β, and Cox2 was found in LNA-anti-miR-132-treated mice. CCl4 treatment increased caspase 3 activity and extracellular vesicles (EVs) in control but not in anti-miR-132-treated mice. Inhibition of miR-132 was associated with augmentation of MMP12 in the liver and Kupffer cells. In vivo and in vitro studies suggest miR-132 targets SIRT1 and inflammatory genes. Using tumor cancer genome atlas data, an increase in miR-132 was found in hepatocellular carcinoma (HCC). Increased miR-132 levels were associated with fibrogenic genes, higher tumor grade and stage, and unfavorable survival in HCC patients. Therapeutic inhibition of miR-132 might be a new approach to alleviate liver fibrosis, and treatment efficacy can be monitored by observing EV shedding.
Insights
microRNAs (miRs) are key regulators in liver disease. Inhibiting miR-132, a microRNA found at high levels in liver fibrosis, reduced scarring and inflammation, suggesting a new therapeutic target.
Area of Science:
- Molecular Biology
- Hepatology
- RNA Biology
Background:
- MicroRNAs (miRs) are small regulatory RNAs implicated in various diseases.
- Liver fibrosis, characterized by excessive scarring and inflammation, involves deregulated gene expression.
- The specific role of miR-132 in liver fibrosis remains to be fully elucidated.
Purpose of the Study:
- To investigate the functional role of miR-132 in liver fibrosis.
- To assess the therapeutic potential of inhibiting miR-132 in liver fibrosis models.
Main Methods:
- Utilized a locked nucleic acid (LNA)-anti-miR approach to inhibit miR-132 in mice.
- Administered carbon tetrachloride (CCl4) to induce liver fibrosis.
- Analyzed liver tissue for fibrogenic markers, inflammatory mediators, and cellular changes.
- Performed in vivo and in vitro studies to identify miR-132 targets.
- Examined TCGA data for miR-132 expression in hepatocellular carcinoma (HCC).
Main Results:
- miR-132 levels were significantly elevated in CCl4-treated mice and patients with fibrosis/cirrhosis.
- Inhibition of miR-132 reduced CCl4-induced fibrogenesis, inflammation, collagen deposition, and expression of α SMA, MCP1, IL-1β, and Cox2.
- miR-132 inhibition decreased caspase 3 activity and extracellular vesicle (EV) shedding.
- MMP12 was upregulated in the liver and Kupffer cells upon miR-132 inhibition.
- miR-132 targets SIRT1 and inflammatory genes, and its increased expression in HCC correlates with fibrogenic genes, advanced tumor stage, and poor survival.
Conclusions:
- Therapeutic inhibition of miR-132 demonstrates potential for alleviating liver fibrosis.
- miR-132 plays a pro-fibrogenic and pro-inflammatory role in the liver.
- EV shedding may serve as a biomarker for monitoring miR-132 inhibition therapy efficacy.
